- Home
- AACT vs FLGT Comparison
AACT vs FLGT Comparison
Compare AACT & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- FLGT
- Stock Information
- Founded
- AACT 2021
- FLGT 2011
- Country
- AACT United States
- FLGT United States
- Employees
- AACT N/A
- FLGT N/A
- Industry
- AACT
- FLGT Medical Specialities
- Sector
- AACT
- FLGT Health Care
- Exchange
- AACT Nasdaq
- FLGT Nasdaq
- Market Cap
- AACT 677.5M
- FLGT 683.5M
- IPO Year
- AACT 2023
- FLGT 2016
- Fundamental
- Price
- AACT $11.00
- FLGT $17.29
- Analyst Decision
- AACT
- FLGT Hold
- Analyst Count
- AACT 0
- FLGT 1
- Target Price
- AACT N/A
- FLGT $22.00
- AVG Volume (30 Days)
- AACT 75.8K
- FLGT 248.2K
- Earning Date
- AACT 01-01-0001
- FLGT 02-26-2025
- Dividend Yield
- AACT N/A
- FLGT N/A
- EPS Growth
- AACT 48.19
- FLGT N/A
- EPS
- AACT 0.43
- FLGT N/A
- Revenue
- AACT N/A
- FLGT $277,761,000.00
- Revenue This Year
- AACT N/A
- FLGT N/A
- Revenue Next Year
- AACT N/A
- FLGT $16.00
- P/E Ratio
- AACT $25.56
- FLGT N/A
- Revenue Growth
- AACT N/A
- FLGT N/A
- 52 Week Low
- AACT $10.47
- FLGT $16.56
- 52 Week High
- AACT $11.02
- FLGT $26.74
- Technical
- Relative Strength Index (RSI)
- AACT 65.98
- FLGT 40.35
- Support Level
- AACT $10.95
- FLGT $16.76
- Resistance Level
- AACT $11.00
- FLGT $17.83
- Average True Range (ATR)
- AACT 0.02
- FLGT 0.65
- MACD
- AACT 0.00
- FLGT -0.09
- Stochastic Oscillator
- AACT 71.43
- FLGT 25.58
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.